CN106456587B - 含有欧米茄-3和白藜芦醇的固体制剂 - Google Patents

含有欧米茄-3和白藜芦醇的固体制剂 Download PDF

Info

Publication number
CN106456587B
CN106456587B CN201580029892.0A CN201580029892A CN106456587B CN 106456587 B CN106456587 B CN 106456587B CN 201580029892 A CN201580029892 A CN 201580029892A CN 106456587 B CN106456587 B CN 106456587B
Authority
CN
China
Prior art keywords
composition
omega
acid
polyunsaturated fatty
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580029892.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456587A (zh
Inventor
G·詹尼尼
M·圣阿涅洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Co ltd
Original Assignee
Alpha Sigmar Jsc
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Sigmar Jsc, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Alpha Sigmar Jsc
Publication of CN106456587A publication Critical patent/CN106456587A/zh
Application granted granted Critical
Publication of CN106456587B publication Critical patent/CN106456587B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
CN201580029892.0A 2014-06-04 2015-03-26 含有欧米茄-3和白藜芦醇的固体制剂 Expired - Fee Related CN106456587B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14001940.7 2014-06-04
EP14001940.7A EP2952180B1 (en) 2014-06-04 2014-06-04 Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
PCT/EP2015/056530 WO2015185239A1 (en) 2014-06-04 2015-03-26 Solid formulations containing omega-3 and resveratrol

Publications (2)

Publication Number Publication Date
CN106456587A CN106456587A (zh) 2017-02-22
CN106456587B true CN106456587B (zh) 2020-03-20

Family

ID=50884650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029892.0A Expired - Fee Related CN106456587B (zh) 2014-06-04 2015-03-26 含有欧米茄-3和白藜芦醇的固体制剂

Country Status (14)

Country Link
US (1) US20170112791A1 (cg-RX-API-DMAC10.html)
EP (1) EP2952180B1 (cg-RX-API-DMAC10.html)
JP (1) JP2017522278A (cg-RX-API-DMAC10.html)
CN (1) CN106456587B (cg-RX-API-DMAC10.html)
AU (1) AU2015271278A1 (cg-RX-API-DMAC10.html)
CA (1) CA2943021A1 (cg-RX-API-DMAC10.html)
EA (1) EA032762B1 (cg-RX-API-DMAC10.html)
ES (1) ES2615630T3 (cg-RX-API-DMAC10.html)
MX (1) MX369782B (cg-RX-API-DMAC10.html)
PL (1) PL2952180T3 (cg-RX-API-DMAC10.html)
PT (1) PT2952180T (cg-RX-API-DMAC10.html)
SI (1) SI2952180T1 (cg-RX-API-DMAC10.html)
UA (1) UA119174C2 (cg-RX-API-DMAC10.html)
WO (1) WO2015185239A1 (cg-RX-API-DMAC10.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
US20100247632A1 (en) * 2009-03-24 2010-09-30 Dong Liang C Stabilized solubility-enhanced formulations for oral delivery
US20110244031A1 (en) * 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384548C (zh) * 2002-08-14 2008-04-30 索莱有限责任公司 具有高液体负载的固体易流动粉末
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
EA201200935A1 (ru) 2009-12-23 2012-12-28 Дефианте Фармасеутика С.А. Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
EP2895144B1 (en) * 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
US20100247632A1 (en) * 2009-03-24 2010-09-30 Dong Liang C Stabilized solubility-enhanced formulations for oral delivery
US20110244031A1 (en) * 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations

Also Published As

Publication number Publication date
WO2015185239A1 (en) 2015-12-10
US20170112791A1 (en) 2017-04-27
ES2615630T3 (es) 2017-06-07
PL2952180T3 (pl) 2017-05-31
EA032762B1 (ru) 2019-07-31
SI2952180T1 (sl) 2017-05-31
UA119174C2 (uk) 2019-05-10
AU2015271278A1 (en) 2016-11-10
MX369782B (es) 2019-11-21
EP2952180A1 (en) 2015-12-09
EA201692399A1 (ru) 2017-03-31
PT2952180T (pt) 2017-03-02
CN106456587A (zh) 2017-02-22
EP2952180B1 (en) 2017-01-25
MX2016013189A (es) 2017-01-16
CA2943021A1 (en) 2015-12-10
JP2017522278A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
JP7726866B2 (ja) ω－３脂肪酸塩とボスウェリア種由来のガム樹脂の抽出物とを含む調製物
JP6538564B2 (ja) エイコサペンタエン酸（ｅｐａ）製剤
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
JP6092843B2 (ja) 神経障害の治療用組成物
JP2014031378A (ja) ビタミンｋ２を含む医薬及び栄養補助製品
CN107405326A (zh) ω3脂肪酸的自乳化组合物
AU2015229240B9 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
WO2024109560A1 (zh) 一种高稳定性脂质体及其制备方法和用途
US20090143484A1 (en) Use of garlic oil to increase bioavailability of coenzyme q-10
WO2014095628A1 (en) Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
JP6552526B2 (ja) ω−３多価不飽和脂肪酸及びレスベラトロールを含む経口投与用均質処方物
CN100475061C (zh) 血管保护剂的组合以及含有它们的制剂
EP2952180B1 (en) Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
CA3046723A1 (en) Omega-3 fatty acid composition for preventing and/or treating cachexia
US20080160001A1 (en) Antihypercholesterolemic Formulation with Less Side-Effects
Santaniello et al. A versatile and stable mixture of fish oil and resveratrol in a powder formulation
CN103479807B (zh) 一种用于脑保护的组合物及其制备方法和用途
WO2015185240A1 (en) Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
HK1233443B (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180115

Address after: Milan Italy

Applicant after: Alpha Sigmar JSC

Address before: Rome Italy

Applicant before: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Bologna, Italy

Patentee after: Alpha sigma Co.,Ltd.

Address before: Milan Italy

Patentee before: Alpha Sigmar JSC

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200320